Using a panel of tumor antigens, the EarlyCDT-Lung test detects the presence of cancerous cells in patients who are at high risk of developing lung cancer including heavy smokers, those exposed to suspect environmental conditions and patients with a CT nodule under surveillance.

The assay, which is developed in collaboration with Kansas-based Oncimmune, provides increased sensitivity, while maintaining higher levels of specificity than other single or multiple antigen tests.

Enzo Biochem president Barry Weiner said the company is focused on providing molecular and esoteric diagnostics that medical practitioners increasingly are relying upon to more timely and effectively predict and treat diseases.

"The EarlyCDT-Lung agreement is recognition of our Clinical Lab’s ability to reach an important segment of physicians in one of the nation’s major market area and of our capability for delivering outstanding assay results, which we have demonstrated with our ColonSentry offering," Weiner added.

"ColonSentry, since its introduction just a few months ago, is growing in use as an early warning test for indications of possible colorectal cancer and the need for a colonoscopy for more extensive investigation.

"Similarly, EarlyCDT-Lung, when used in conjunction with diagnostic imaging, has the potential to aid in the identification of possible lung cancer when treatment can be most successful at a very early stage."